Inclusion criteria For entire trial:

          1. - Adult > or = 18 years old

          2. - has signed the Informed Consent Form (ICF)

          3. - has at least one measurable or non-measurable disease as per RECIST 1.1

          4. - has tumor tissue available for the analysis as described in the protocol

          5. - has adequate bone marrow and organ function as defined in the protocol

          6. - is able to swallow and retain oral medication for the dose escalation part, ALL
             above PLUS

          7. - has a histologically-confirmed, advanced unresectable solid tumors who have
             progressed on standard therapy (or not been able to tolerate) within three months
             before screening/baseline visit or for whom no standard anticancer therapy exists.

          8. - has an Eastern Cooperative Oncology Group (ECOG) performance status ≤2 For dose
             expansion part, patient has ALL of above first six criteria PLUS either: 9- has a
             histologically/cytologically-confirmed HNSCC as detailed in the protocol and an ECOG
             performance status ≤ 1 or:

               -  Patient is a Female with a histologically and/or cytologically confirmed
                  diagnosis of breast cancer as detailed in the protocol and an ECOG performance
                  status ≤ 1

        Common exclusion criteria to Dose escalation and Dose expansion parts:

          1. - has received previous treatment with a PI3K or AKT inhibitor as described in the
             protocol

          2. - has a known hypersensitivity to paclitaxel or other products containing Cremophor

          3. - has a contraindication to use the standard pre-treatment for paclitaxel

          4. - has a primary central nervous system (CNS) tumor or CNS tumor involvement as
             detailed in the protocol

          5. - has not recovered to grade 1 or better (except alopecia) from related side effects
             of any prior antineoplastic therapy

          6. - has received radiotherapy > or = 4 weeks prior to starting study drugs, with
             exception of palliative radiotherapy, who has not recovered from side effects of such
             therapy to baseline or Grade ≤ 1 and/or from whom ≥ 30% of the bone marrow was
             irradiated

          7. - has peripheral sensory neuropathy with functional impairment (CTC grade 2 neuropathy
             or higher)

          8. - has undergone major surgery ≤ 4 weeks prior to starting study treatment or who has
             not recovered from side effects of such procedure

          9. - has a clinically significant cardiac disease or impaired cardiac function as
             detailed in the protocol

         10. - is currently receiving medication with a known risk of prolonging the QT interval or
             inducing Torsades de Pointes (TdP) and the treatment cannot either be discontinued or
             switched to a different medication prior to starting study drug treatment

         11. - has diabetes mellitus requiring insulin treatment and/or with clinical signs

         12. - has impaired gastrointestinal (GI) function or GI disease as described in the
             protocol

         13. - has a known positive serology for human immunodeficiency virus (HIV), active
             Hepatitis B, and/or active Hepatitis C infection

         14. - has any other condition that would, in the Investigator's judgment, preclude
             patient's participation in the clinical study due to safety concerns or compliance
             with clinical study procedures

         15. - is currently receiving treatment with drugs known to be moderate or strong
             inhibitors or inducers of isoenzymes CYP3A or CYP2C8 as detailed in the protocol

         16. - is currently receiving treatment with agents that are metabolized solely by CYP3A
             and/or have a narrow therapeutic window

         17. - has a history of another malignancy within 2 years prior to starting study
             treatment, except cured basal cell carcinoma of the skin or excised carcinoma in situ
             of the cervix

         18. - Patient has a history of non-compliance to medical regimen or inability to grant
             consent

         19. - Pregnant or nursing (lactating) women

         20. - does not apply highly effective contraception during the study and through the
             duration as defined in the protocol

        For the HNSCC patient's cohort additional exclusion criteria are:

        21- Treatment with more than one prior chemotherapy for recurrent/metastatic disease as
        detailed in the protocol 22- Prior taxane treatment for metastatic disease additional
        exclusion criteria for breast cancer patients' cohort:

        - has received any prior cytotoxic therapy for the inoperable locally advanced (recurrent
        or progressive) or metastatic disease, or who had a progression/recurrent disease within 6
        months after completion of an adjuvant/neoadjuvant therapy as described in the protocol

        Other protocol-defined inclusion/exclusion criteria may apply